Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Clofarabine in the treatment of poor risk acute myeloid leukaemia.
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Clofarabine in the treatment of poor risk acute myeloid leukaemia.
Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematol Oncol. 2010 Sep; 28(3):118-23.
View in:
PubMed
subject areas
Adenine Nucleotides
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Arabinonucleosides
Female
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Retrospective Studies
Risk Factors
Young Adult
authors with profiles
Michael Joseph O'Dwyer